Influvac Sub-Unit

Influenza virus vaccine (subunit), the active ingredient in Influvac Sub-Unit, is a vaccine presented as a subunit formulation for intramuscular/subcutaneous use. It induces immunity to prevent influenza infection caused by influenza A and B viruses in the general population, including high‑risk groups.

GNH USA supplies Influvac Sub-Unit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides cold‑chain logistics for global distribution.

Influvac Sub-Unit is used to prevent influenza caused by viruses of the A and B families.

- Seasonal influenza: reduces the risk of infection and associated complications in the general population. - Elderly and immunocompromised patients: provides protective immunity to lower severe disease rates. - Healthcare workers: helps limit transmission of influenza in clinical settings.

Like other injectable vaccines, Influvac Sub-Unit may be associated with local and systemic reactions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Redness or swelling: transient erythema or edema around the injection area. - Low‑grade fever: temperature rise up to 38°C within 24‑48 hours. - Headache or muscle aches: transient discomfort lasting a day or two.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder that may follow vaccination. - Seizures or high fever: uncommon but potentially serious systemic events. - Hypotension: sudden drop in blood pressure after injection. - Severe local reaction: extensive swelling or necrosis at the injection site.

Prior to vaccination, certain safety considerations should be observed.

- Assess allergy history: avoid in individuals with known severe allergy to any vaccine component. - Delay vaccination: postpone if moderate or severe acute illness is present. - Monitor after injection: observe for at least 15 minutes for signs of anaphylaxis. - Use with caution in immunosuppressed patients: vaccine may elicit reduced immune response. - Do not freeze: keep refrigerated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac Sub-Unit may interact with other medical products; awareness of key interactions helps ensure safety.

Major Interactions (Avoid): - Live attenuated vaccines: concurrent administration may interfere with immune response. - Immunosuppressive therapy (e.g., high‑dose steroids, chemotherapy): may diminish vaccine efficacy.

Moderate Interactions (Monitor Closely): - Antipyretics (acetaminophen, ibuprofen): may mask post‑vaccination fever. - Antihistamines: may reduce local reaction but do not prevent systemic response. - Blood products given within 48 hours: may affect antibody development.